Today: 21 May 2026
Browse Category

LSE:TSCO 29 September 2025 - 8 December 2025

Tesco is Giving Away Free ‘Perfectly Imperfect’ Christmas Trees in 2025 – How the Wonky Tree Giveaway Works (and the Other Festive Freebies You Should Know About)

Tesco is Giving Away Free ‘Perfectly Imperfect’ Christmas Trees in 2025 – How the Wonky Tree Giveaway Works (and the Other Festive Freebies You Should Know About)

Tesco gave away hundreds of free “Perfectly Imperfect” real Christmas trees at 10 UK stores on Saturday, 6 December 2025, as part of its festive campaign. The one-day event drew large crowds, with trees available from 10am on a first-come, first-served basis. Tesco encouraged voluntary donations to FareShare and The Trussell Trust.
7 December 2025
·
Tesco PLC (LON: TSCO) Stock Near 52‑Week Highs: Buyback, Dividend Outlook and 2026 Forecasts as of 4 December 2025

Tesco PLC (LON: TSCO) Stock Near 52‑Week Highs: Buyback, Dividend Outlook and 2026 Forecasts as of 4 December 2025

Tesco shares traded around 451–453p on 4 December 2025, up more than 20% year to date and ahead of the FTSE 100. The stock rebounded after an April profit warning, with upgraded full-year profit guidance in October following strong first-half results. Tesco’s £1.45bn share buyback and rising dividends supported the rally. The company now forecasts £2.9–3.1bn in adjusted operating profit for 2025/26.
4 December 2025
··
‘Do Not Eat’ Warning: Asda Duck Spring Rolls Recalled Today as Tesco Salad, Lidl and Poundland Nuts Pulled in UK Supermarket Safety Alert – 28 November 2025

‘Do Not Eat’ Warning: Asda Duck Spring Rolls Recalled Today as Tesco Salad, Lidl and Poundland Nuts Pulled in UK Supermarket Safety Alert – 28 November 2025

Asda has recalled its 10 Mini Duck Spring Rolls with Hoisin Dip after a misprinted use-by date extended shelf life by a month, raising food poisoning concerns, the Food Standards Agency said Friday. Shoppers are told not to eat the product and to return it for a refund. Major supermarkets including Tesco, Lidl, Poundland, Aldi, and Sainsbury’s have also issued recalls this week.
28 November 2025
···
Tesco PLC (TSCO) Ramps Up £1.45bn Buyback as Shares Trade Near 52‑Week High – Latest News for 27 November 2025

Tesco PLC (TSCO) Ramps Up £1.45bn Buyback as Shares Trade Near 52‑Week High – Latest News for 27 November 2025

Tesco confirmed it bought and will cancel 4.24 million shares on 26 November under its £1.45bn buyback, reducing the share count to about 6.44 billion. Shares traded near 455p late Thursday morning, close to 52-week highs. Since April, Tesco has repurchased nearly 299 million shares for £1.21bn. The company raised its profit forecast in October and paid a higher interim dividend on 21 November.
27 November 2025
··
Tesco (TSCO) Extends £1.45bn Buyback as Shares Hover Near Highs — 26 November 2025 Investor Update

Tesco (TSCO) Extends £1.45bn Buyback as Shares Hover Near Highs — 26 November 2025 Investor Update

Tesco bought back 4.87 million shares for £21.7 million on 25 November, bringing its £1.45 billion buyback programme to 82% completion. CEO Ken Murphy and CFO Imran Nawaz increased their holdings last week. Tesco shares traded near 445p Tuesday, valuing the group at £28.7 billion. The company also announced new charity partnerships and Christmas promotions in the UK and Ireland.
26 November 2025
··
Tesco Shares Soar After Double‑Digit Dividend Hike: What Investors Need to Know

Tesco (LSE: TSCO) hits fresh 52‑week high before reversing as UK grocery inflation cools — 11 November 2025

Tesco shares hit a 52-week high of 480.50p in early London trading before falling to around 460p by midday. Grocery inflation slowed to 4.7% in the four weeks to 2 November as Christmas promotions intensified. Tesco’s sales rose 5.9% over 12 weeks, lifting market share to 28.2%. The company continues its £1.45bn buyback ahead of the holiday season.
11 November 2025
···
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European stocks closed higher Monday, with the FTSE 100 up 0.5% and the STOXX 600 gaining 0.2% as healthcare and tech outperformed. GSK surged 3.3% after CEO Emma Walmsley’s exit was announced; AstraZeneca rose 1.3% on plans for a New York listing. Lufthansa said it will cut 4,000 jobs. Oil fell 0.6% on resumed Iraqi Kurdish exports and OPEC+ supply news; gold hit a record $3,812 an ounce.
29 September 2025
·······
1 2 3

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop